HISTOGEN

[Joda]

για ενημερωτικο σκοπο πανω στην inercytex αυτα ειναι τα αποτελεσματα που ειχαν ανακοινωσει στην φαση 2 περσυ στις 17/03/2008..http://tressless.com/2008/03/17/intercytex-phase-ii-hair-multiplication-completed-trial-results/
ακομα ειναι στην φαση 2 καθως χρειαζονται αρκετες δοκιμες πριν περασουν στην φαση 3.το προιον που δοκιμαζουν λεγεται intercytex-trc(TRC stands for Trichocyte. This is the product name for Intercytex's Hair Multiplication research. 'TRC is an autologous hair regeneration therapy, a suspension of human dermal papilla cells, intended for the treatment of male pattern baldness and female diffuse alopecia. It is intended that TRC will be used by specialists in hair tr*nspl*nt centres, dermatologists and plastic surgeons to treat patients with hair thinning or hair loss.' ).αν βγει κατι θα γινεται απο πλαστικους χειρουργους η απο γιατρους μεταμοσχευσεων.

[Joda]

οπως σας ειχα πει 26/03/2009 η inercytex θα μας ενημερωσει για τα αποτελεσματα των δοκιμων της,της φασης 2 που τελειωσαν στις 31/12/2008.τωρα ψαχνουν για επενδυτη για να συνεχισουν και να βελτιωθουν.εχει δρομο ακομα.
 ICX-TRC
Product description
ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These cells are able to
stimulate the generation of new hairs when injected into the scalp in close proximity to the epidermal cells
which generate the hair. It is intended that ICX-TRC will be used by specialists in hair tr*nspl*nt centres,
dermatologists and plastic surgeons to treat patients with hair thinning or hair loss.

Clinical development
We have now completed our Phase II study, which was conducted by Dr Bessam Farjo in
Manchester, to examine different ways to deliver the DP cells. DP cells naturally reside at the base of all
hair follicles and are known to control the growth and cycling of hair. It has been known by scientists for
many years that these cells can also interact with epidermal cells in the skin and induce them to form new
hairs. For this to occur however, the DP cells need to be placed close to the epidermal cells which in turn
need to be in a correct inducible state to respond to the DP signals.
This trial was designed to examine the effect of different DP delivery techniques and methods to ensure
that the epidermal cells were in the correct state to respond to the signals and produce new hairs.

In this study, subjects were injected 900 times with 1μl aliquots of DP cells in a large area which was
photographed at the end of the study. Subjects were also injected in a smaller area, divided into two
sections - counts were obtained by shaving and photographing the two small sections of scalp,
injecting them multiple times (either 1 injection of 50 μl or 50 injections of 1 μl) with living DP cell
suspension and then applying a specialised image analysis system to provide a total hair count. In
these small sections, all 19 subjects in the trial were treated using a range of injection and scalp prestimulation
techniques; the first 6 subjects were injected without stimulation of the scalp. In the
remaining 13 subjects the resident hair producing (epithelial) cells were stimulated at the time of
delivery of the DP cells in one of the two treatment sites.
13 subjects completed the 48-week trial with 6 subjects lost to follow-up. Of the 13 subjects completing
the trial the data showed that:

· 65% (11/17) of the treated sites in the non-stimulated group responded to the treatment by
increasing numbers of hairs of all sizes
· 71% (12/17) of the treated sites in the non-stimulated group responded to the treatment by
increasing numbers of hairs over 30 micron in diameter
· 78% (7/9) of the treated sites in the stimulated group responded to the treatment by
increasing numbers of hairs of all sizes
· 100% (9/9) of the treated sites in the stimulated group responded to the treatment by
increasing numbers of hairs over 30 micron in diameter
· The overall take rate (number of hairs produced per 100 injections) in the stimulated areas
was
o 40% (n=6) for hairs of all sizes
o 18% (n=6) for hairs over 30 micron in diameter

The larger (900 injection) area photographs have not yet been analysed.
These data are consistent with the interim data reported last September and further confirm the
hypothesis that new hair production is improved by pre-stimulation of the scalp, leading to an
interaction between the injected cells and the resident hair producing cells.

Dr Bessam Farjo, the Principal Investigator for this study, said “We have learned a lot from this trial,
including the different ways in which these cells can be delivered and that it is possible to do one
thousand of these injections in a relatively short period of time and at little discomfort to the patient. I
am very encouraged by this data both in the increase in the total number of hairs in the treated site but
more importantly by the increase in thicker hairs, those over 30 micron.”
Further results of the trial will be presented later in the year.

Commercial opportunity
ICX-TRC overcomes one of the principal drawbacks of conventional tr*nspl*nts which is that the
outcome is limited by the amount of donor hair available. By using the Intercytex cell therapy technique
almost limitless hair regeneration is possible in a less invasive procedure. Furthermore, treatment can
commence early on in the hair loss process with retreatment available in subsequent years. The barrier
to commercial success for ICX-TRC is relatively low, being the ability to increase hair count in
tr*nspl*nted or thinning areas.
We believe the continued development of ICX-TRC would best be carried out in partnership with a
specialist in the aesthetics field. We do not intend to finance the continuation of clinical and commercial
development of ICX-TRC beyond the current Phase II trial and shall seek to sign a partner when we have
the complete data package from this trial. Intercytex has granted Bosley, the largest chain of hair
tr*nspl*nt clinics in the US, an option to negotiate distribution rights to the product.

Intellectual Property
We have split our cell delivery patent application into three separate applications in the US reflecting
additional techniques that are being developed. We have also filed a patent application relating to our
observation that epidermal stimulation pre-treatment appears to enhance hair follicle formation. Two
other previously filed patent applications relating to the method of culturing the dermal papilla cells have
been published and are undergoing international examination.

SEE LINK
http://www.intercytex.com/icx/news/releases/2009/2009-03-26/2009-03-26.pdf

[Σπύρος]

όλη μέρα σήμερα βουίζουν τα δελτία ειδήσεων για το τέλος της αραίωσης/τριχόπτωσης - μιλούν για τεχνική βλαστοκυττάρων από το υποδόριο λίπος,κατάψυξη και διαφοροποίησή τους σε νέα κύτταρα ριζικής μεταμόσχευσης στις περιοχές αραίωσης...

άντε.....
κουράγιο αδέλφια....
φάγαμε τον γάιδαρο και έμεινε η γ%μ@ουρά!!!

[Παναγιωτης]

joda σε διαβαζουμε . . . thanks για την ενημερωση που προσφερεις στο forum

[baybars]

ΡΕ ΛΕΣ??? ΓΙΑ ΝΑ ΔΟΥΜΕ....

[Georgex6]

η Histogen, Α.Ε., αποκάλυψε για πρώτη φορά τα αποτελέσματα των προκαταρκτικών κλινικών δοκιμών της για το προϊόν της HSC, στη διεθνή κοινοτητα  στην ετήσια επιστημονική συνεδρίαση των χειρούργων μαλλιων στο Άμστερνταμ 22-26 Ιουλίου 2009 (ISHRS) Annual Scientific Meeting in Amsterdam July 22-26, 2009). Τα αποτελέσματα ήταν ενθαρρυντικά…

http://www.histogeninc.com/aboutus/news_events.htm#24

[Παναγιωτης]

ελπιζουμε παντα στα καλυτερα

[baybars]

η Histogen, Α.Ε., αποκάλυψε για πρώτη φορά τα αποτελέσματα των προκαταρκτικών κλινικών δοκιμών της για το προϊόν της HSC, στη διεθνή κοινοτητα  στην ετήσια επιστημονική συνεδρίαση των χειρούργων μαλλιων στο Άμστερνταμ 22-26 Ιουλίου 2009 (ISHRS) Annual Scientific Meeting in Amsterdam July 22-26, 2009). Τα αποτελέσματα ήταν ενθαρρυντικά…

http://www.histogeninc.com/aboutus/news_events.htm#24

Παντως, αν κρινω απο τις φωτογραφιες, τα αποτελεσματα regrowth σε 3 μηνες ειναι καλυτερα απο αυτα που δινει (θεωρητικα παντα) το regaine σε 6 μηνες...μακαρι, τι να πω...

[Joda]

το 2015 λενε οτι θα εχουν προιον για να δουμε..μακαρι να γινει...

[Georgex6]

Αυτο θα ελεγα κι εγω φιλε loda με προλαβες  (αν και λενε οτι εκτος usa μπορει να βγει και πιο μπροστα)
παντως οποιοις θελει ας διαβασει τη συνεντευξη  (Interview with Gail Naughton, PhD, CEO, Chairman of the
Board, Histogen Inc) ειναι παρα πολυ ενδιαφερουσα
http://www.ishrs.org/PDF/F4-2009.pdf εξηγει τι ειναι-αποτελεσματα-γιατι διαλεξαν τις ονδουρες κ.α.

[Georgex6]

"12. Are the hairs being produced also androgen sensitive
and, if this is the case, will the treatment need to be
permanently given?
Histology is being performed and we should be able to
obtain those data."
διαβαζοντας αυτο το αποσπασμα μαλλον βγαινει το συμπερασμα οτι οι νεες τριχες θα ειναι ευαλωτες στα ανδρογονα αλλα μιλαμε για ενα πολυ ισχυρο growth stimulant

[Joda]

πιο νωρις δεν το κοβω....μολις περσυ αρχισαν τις δοκιμες και αυτο απαιτει χρονια..εμενα προσωπικα μ αρεσει που λενε ξερεις δεν θα εχουμε κατι τωρα αμεσα γιατι αν βγαλουν κατι θα ειναι λογικα κατι πολυ καλυτερο απο την μινοξιδιλη και αυτος πιστευω πως ειναι ο στοχος τους...

[Joda]

Histogen exec sees growing promise in stem cell technology
By ELIZABETH MALLOY
Thursday, October 29, 2009

For Gail Naughton, one of the most exciting things about her company Histogen's recent clinical trial is just how fast they're seeing results.
The trial, conducted in South America, is for a hair re-growth treatment. Looking at pictures of patient samples, the before and after differences are easy to see.
"You don't have to be a hair expert to see there are hairs where there were not (before) and they're thicker hairs," Naughton said, looking at photos of patients who received Histogen's hair re-growth treatment in South America. "One injection, we were able to increase it by 100 new hairs."
Hair regrowth is just one of the possible treatments Histogen hopes to generate with its stem cell technology. The company also has the potential to grow new organ cells, nerve cells in the spine, even treat cancer. But Naughton said hair treatments would have a huge initial market, which can bring in funding for other more serious conditions.
"Hair can really generate a lot of excitement and help us raise the cash we need to develop the other products," she said.
Histogen's chairwoman and chief executive, Naughton is somewhat of a rarity in that she is both a scientist and a businesswoman. She is working to make this less of a rarity in her other job -- as dean of San Diego State University's College of Business Administration. There, she has helped develop a joint Ph.D. and MBA program that will teach more scientists business skills, and vice versa.

Gail Naughton
A native of Brooklyn, N.Y., Naughton was a scientist first, only learning the business side when she started her first company, Advanced Tissue Sciences Inc., in 1991. The technology Histogen is based on is from Naughton's own research.
While Histogen can be considered a stem cell company, the treatments the company is working on uses a protein secreted by stem cells, rather than the actual cells themselves. The company gets the protein using a unique strategy.
"The whole premise of Histogen is that if you go and grow human cells under conditions that are embryonic-like, the cells will revert back, and become embryonic," she explained.
One of the advantages scientists have long seen with embryonic stem cells is that they secrete a kind of protein called WNT proteins. These are the proteins that signal to cells how to differentiate, or turn into the various muscle, bone, organ and blood cells they should grow into.
Researchesr believed that they could isolate WNT proteins and use them to stimulate tissue growth and regrow things like organs, skin and hair.
Naughton's discovery with Histogen, which was based on other researchers' work, was that by growing cells in an embryonic environment -- low-gravity and low-oxygen -- within a few days, the cells would revert to their embronic state. This means the company could get WNT proteins without having to drestroy actual embryoes.
"We're not the basic, 'A-ha!' discovery research (company)," she explained. "We're there saying, 'We know the composition of what we have, we know what's unique about it, let's go to the literature and see what other people have found to be important with these and let's go after the therapuetic areas, which are our greatest need right now.'"
While it conducts research on different therapuetic treatments, Histogen has products on the market which help generate some cashflow, though not enough to fully fund the company yet. The company sells a stem cell product, and is awaiting FDA approval for a wound care product.
The hair product could be on the market in Asia within the next two years.
Histogen has suffered some setbacks in the last year. The company had 38 employees until last January, when it was hit with a lawsuit over patent infrigement. Histogen had to lay most of the staff off, but still has 11 full-time employees. Naughton said that after another round of fundraising, they hope to begin rehiring.
The company is currently raising money to expand its hair re-growth trial in Asia.
As both the executive officer of Histogen and the dean of SDSU's business school, Naughton acknowledged that she's a very busy woman. She works about seven days a week, whether it's raising venture funding for the company, reading up on new possibilities for WNT proteins or creating international studies programs for her business students. Still, she said, she wouldn't have it any other way.
"By being able to be involved with both, I keep myself at a good balance," she said. "I love what I do."

με λιγα λογια λεει οτι μπορει να ειναι στην αγορα της ασιας σε 2 χρονια...για να δουμε..ειναι νωρις τωρα...οταν ερθει η ωρα κ αν ερθει τοτε θα το κοιταξουμε σοβαρα γιατι μεχρι να γινει πραξη ολα ειναι ισχυρισμοι..

[Georgex6]

http://www.baldtruthtalk.com/showthread.php?t=1557
πολυ ενδιαφερον ερωτηση  From what I gathered Histogen’s HSC Complex will be an injectable that will grow new hair follicles. Does this mean that all you would have to do is have a couple of sessions of this procedure a year to keep a full head of hair, or will you still have to undergo hair tr*nspl*nt surgery with the process?
και απανταει οτι με μια μονο εφαρμογη και εχουμε 25 % αυξηση τριχων και αυτες που ειναι σε τελογενη φαση αλλα και δημιουργια νεων θυλακων και οσο πιο πολλες δοσεις τοσο καλυτερο θα ειναι και το αποτελεσμα επισης αναφερει οτι δε θα χρειαζονται μεταμοσχευσεις πλεον και οτι αν καποιος εχασε τα μαλλια του πχ στα 30 τοτε τα μαλλια που θα βγαλει δε θα του πεσουν για 30 χρονια  πολλυ ωραια ολα αυτα ε?/?
παντως απο τι διαβαζα σε ξενα forum (η αληθεια ειναι οτι το σκεφτηκα κι εγω) καποιοι χρησιμοποιουν το regenica for skin στα μαλλια.ενταξη σιγουρα δεν ειναι το ιδιο αλλα σκεφτηκα να το παραγγειλω για τη mother και μου χει μπει μια ιδεα   

[haircloningnow]

δηλαδη ρε παιδια λετε μεσα στα επομενα 4-5 χρονια να εχουμε κατι πολυ καλο απο αυτη την histogen??πραγματικα μακαρι....!!!παντως οποτε μπαινω στο site μας και βλεπω topic που να αφορα τις μελλοντικες θεραπειες χαιρομαι πολυ...!!γιατι με τις ηδη υπαρχουσες φως δεν προκειται να δουμε,,,περα απο το φως της αντανακλασης της φαλακρας μας...!!τι να πω ελπιζω πολυ στην histogen καθως επισης και στην aderans!εντωμεταξυ κατι ακουσα οτι ο φοιτητης απο την oxford δεν το εχει παρατησει....ακομα!σχετικα με το ΤRX2 δηλαδη λεω!για να δουμε,,,,,μια 5ετια δινει για ολα....αλλιως μετα τα παιδια μας αν δουνε κατι καλο!